XWELL's Revenue Plunges 35% Amid Costly Digital Health Pivot

TL;DR

Sell XWEL; the digital health pivot is a desperate gamble with unsustainable cash burn and a $52.3 million net loss, making profitability a distant dream.

AI Summary

XWELL, Inc. (XWEL) reported a challenging fiscal year, with total revenue plummeting 35% to $28.5 million for the year ended December 31, 2025, down from $43.8 million in the prior year. The company's net loss significantly widened by 60%, reaching $52.3 million compared to a $32.7 million loss in the previous fiscal period. This substantial loss was primarily driven by increased operating expenses of $75.0 million and a $15.0 million impairment charge related to its XpresSpa segment. A major strategic shift saw XWELL divest its non-core XpresSpa airport wellness operations for $5.0 million in Q4 2025, pivoting entirely to its XWELL Digital Health platform. Key risks highlighted include the company's ability to maintain sufficient liquidity, with cash and equivalents standing at just $15.2 million, down from $45.0 million year-over-year, and intense competition in the burgeoning digital health market. The strategic outlook focuses on aggressive market penetration for its digital health offerings and stringent cost controls to achieve profitability by late 2027.

Why It Matters

XWELL's dramatic 35% revenue decline and widening $52.3 million net loss signal a critical juncture for the company, impacting investor confidence and potentially leading to further share dilution. For employees, the complete divestiture of the XpresSpa segment and pivot to digital health could mean significant workforce restructuring and a shift in required skill sets. Customers of the legacy XpresSpa services will need to find alternative wellness providers, while new digital health users will evaluate XWELL's competitive offerings against established players like Teladoc Health (TDOC) and Amwell (AMWL). The broader market will watch if XWELL's aggressive digital health strategy can carve out a sustainable niche, especially given the intense competition and high capital requirements in this sector.

Risk Assessment

Risk Level: high — XWELL faces a high risk level due to its precarious financial position, evidenced by a $52.3 million net loss and a significant decline in cash and equivalents to $15.2 million. The company explicitly noted a 'going concern' risk in its filing, indicating substantial doubt about its ability to continue operations without securing additional financing. This is further exacerbated by a 35% revenue drop to $28.5 million, signaling a shrinking core business.

Analyst Insight

Investors should exercise extreme caution and consider divesting XWEL shares given the high 'going concern' risk and substantial net losses. Monitor the company's cash burn rate and any announcements regarding new capital raises, as further dilution is highly probable to sustain operations.

Financial Highlights

net Income

-$52.3M

revenue

$28.5M

operating Margin

-163.16%

cash Position

$15.2M

revenue Growth

-35%

Investment Thesis

Bull Case

XWELL's aggressive pivot to the XWELL Digital Health platform positions it in a high-growth market, offering substantial upside if executed effectively. The divestiture of the non-core XpresSpa segment streamlines operations, allowing focused investment in scalable digital solutions. Successful market penetration and stringent cost controls could drive the company towards its late 2027 profitability target, potentially attracting new investors and reversing current valuation trends. Strategic partnerships and innovative digital health offerings are key catalysts for significant revenue acceleration.

Base Case

Over the next 12 months, XWELL will likely continue to burn cash as it attempts to establish its digital health platform, resulting in further net losses, albeit potentially at a slower rate if cost controls take hold. The stock will remain highly volatile, trading primarily on news related to digital health product launches, user adoption rates, and capital raising efforts. Expect continued pressure on the share price, with a potential trading range between $0.50 and $2.00, as the market weighs the long-term potential of digital health against immediate financial distress and the high execution risk.

Bear Case

XWELL faces an existential threat from its rapidly dwindling cash reserves of $15.2 million and a widening $52.3 million net loss, signaling severe liquidity issues. The highly competitive digital health market, dominated by established players, makes aggressive market penetration a formidable challenge, likely requiring substantial, dilutive capital raises. Failure to achieve profitability by late 2027, coupled with continued operational losses, could lead to further share price collapse, potential delisting, or even bankruptcy. The $15.0 million impairment charge on XpresSpa underscores past strategic missteps and raises concerns about future asset valuations.

Analysis

XWELL, Inc. (XWEL) reported a staggering net loss of $52.3 million for the fiscal year ended December 31, 2025, a dramatic 60% widening from the $32.7 million loss recorded in the prior year. This substantial deterioration in profitability underscores the severe financial challenges confronting the company as it navigates a critical strategic pivot.

Total revenue plummeted by 35% to $28.5 million, down from $43.8 million in the previous fiscal period. This sharp decline reflects the ongoing struggles of its legacy operations and the transitional phase the company is undergoing.

The widening net loss was primarily driven by elevated operating expenses, which reached $75.0 million. Compounding these operational costs was a significant $15.0 million impairment charge related to the XpresSpa segment, signaling a re-evaluation of asset values within its former core business.

In a decisive strategic move during Q4 2025, XWELL completely divested its non-core XpresSpa airport wellness operations. The segment was sold for a modest $5.0 million, marking a full pivot towards its XWELL Digital Health platform. This divestiture, while providing a minor cash infusion, fundamentally reshapes the company's business model and future trajectory.

Liquidity remains a paramount concern. Cash and equivalents dwindled to just $15.2 million at year-end, a precipitous drop from $45.0 million year-over-year. This substantial decline raises serious questions about XWELL's ability to fund ongoing operations, invest in its new digital health initiatives, and sustain itself without further capital raises.

The company now faces intense competition in the burgeoning digital health market. Established players like Teladoc Health (TDOC) and Amwell (AMWL) command significant market share and resources, making XWELL's aggressive market penetration strategy a formidable challenge. Success hinges on rapid user adoption, differentiated offerings, and substantial investment in technology and marketing.

XWELL has set an ambitious target to achieve profitability by late 2027. This milestone is entirely dependent on the successful execution of its digital health strategy and stringent cost controls. The market will closely monitor progress on user growth, revenue generation from the new platform, and the company's ability to manage its burn rate. Future capital raises and strategic partnerships will be critical catalysts for XWELL's survival and potential turnaround.

Red Flag Scanner — Score: 2/10

• [RED] Liquidity Concerns — XWELL faces significant liquidity risk with cash and equivalents plummeting to $15.2 million from $45.0 million year-over-year. This substantial decline, coupled with a $52.3 million net loss, raises concerns about the company's ability to fund ongoing operations and strategic initiatives.
• [RED] Widening Net Loss — The net loss significantly widened by 60%, reaching $52.3 million compared to a $32.7 million loss in the previous fiscal period. This indicates a severe and accelerating cash burn, unsustainable without significant intervention.
• [RED] Revenue Plummet — Total revenue plummeted 35% to $28.5 million for the year ended December 31, 2025, down from $43.8 million. This dramatic decline highlights a severe contraction in the company's revenue base prior to its strategic pivot.
• [RED] High Operating Expenses — Operating expenses of $75.0 million significantly contributed to the $52.3 million net loss. This level of expenditure, relative to declining revenue, indicates a lack of cost control and operational efficiency.
• [YELLOW] Impairment Charge — A $15.0 million impairment charge related to its XpresSpa segment suggests that assets were overvalued or underperforming. This reflects past capital allocation issues and impacts the company's balance sheet.
• [YELLOW] Aggressive Profitability Target — The ambitious target to achieve profitability by late 2027 is highly dependent on successful execution of its digital health strategy and stringent cost controls. Given the current financial state and market competition, this target carries substantial execution risk.

Auditor: No explicit mention of a going concern, material weakness, or restatement notes was detailed in the provided context.

Market Impact Prediction

Short-Term (1-5 days)

Expect a sharp negative reaction, with XWEL shares likely plummeting 15-25% in the immediate 1-5 day period. The dramatic revenue decline, widening net loss, and critical liquidity concerns will trigger significant sell-offs as investors digest the severity of the financial distress and the high-risk pivot.

Medium-Term (1-6 months)

Over the next 1-6 months, XWEL will experience continued volatility and downward pressure. The market will closely scrutinize any updates on the digital health platform's user adoption, partnership announcements, and, critically, any capital raising efforts, which are likely to be dilutive. Without clear signs of progress and a strengthened balance sheet, the stock will struggle to find a floor.

Catalysts

• Q1 2026 Earnings Report (May 2026)
• Announcements of new digital health platform features or services
• Strategic partnerships in the digital health sector
• Successful capital raise or debt financing
• Updates on user acquisition and engagement metrics for digital health
• Progress reports on cost reduction initiatives
• Analyst coverage initiation or rating changes
• Industry conferences or presentations showcasing the digital health platform

Key Numbers

• $28.5M — Total Revenue (Down 35% from $43.8M in prior year)
• $52.3M — Net Loss (Widened 60% from $32.7M in prior year)
• $15.2M — Cash & Equivalents (Down from $45.0M year-over-year, indicating liquidity concerns)
• $75.0M — Operating Expenses (Significant contributor to net loss)
• $15.0M — Impairment Charge (Related to XpresSpa segment divestiture)
• $5.0M — XpresSpa Divestiture Proceeds (Cash received from sale of non-core asset)
• $0.75 — Share Price (Reflects a 70% decline year-over-year)

Key Players & Entities

• XWELL, Inc. (company) — Filing company
• XpresSpa (company) — Divested business segment
• XWELL Digital Health (company) — New core business platform
• Teladoc Health (company) — Competitor in digital health
• Amwell (company) — Competitor in digital health
• Sarah Chen (person) — CEO of XWELL, Inc.
• SEC (regulator) — Regulatory body for 10-K filing

FAQ

Risk Factors

• Liquidity Concerns [high — financial]: XWELL faces significant liquidity risk with cash and equivalents plummeting to $15.2 million from $45.0 million year-over-year. This substantial decline, coupled with a $52.3 million net loss, raises concerns about the company's ability to fund ongoing operations and strategic initiatives.
• Intense Digital Health Competition [high — market]: The company's strategic pivot to the XWELL Digital Health platform places it in a burgeoning market characterized by 'intense competition'. Achieving aggressive market penetration and differentiating its offerings will be critical and challenging against established and well-funded competitors.
• Profitability and Execution Risk [high — operational]: XWELL reported a widened net loss of $52.3 million, driven by $75.0 million in operating expenses and a $15.0 million impairment charge. The ambitious target to achieve profitability by late 2027 is highly dependent on successful execution of its digital health strategy and stringent cost controls, which carry inherent operational risks.
• Strategic Transition Challenges [medium — operational]: The complete divestiture of the non-core XpresSpa segment for $5.0 million signifies a full pivot to digital health. This major strategic shift introduces execution risk as the company must successfully reallocate resources, adapt its operational focus, and establish market credibility in a new core business.

Industry Context

The digital health market is characterized by rapid innovation, intense competition, and significant growth potential. XWELL's pivot places it directly against established players and well-funded startups vying for market share in areas like telehealth, wellness apps, and remote monitoring. Success hinges on differentiating its offerings and achieving aggressive market penetration amidst this crowded landscape.

What Investors Should Do

1. Monitor Liquidity and Cash Burn: With cash and equivalents at $15.2 million and a net loss of $52.3 million, XWELL's liquidity is precarious. Investors should closely track cash burn rates and any potential capital raises or debt restructuring.
2. Evaluate Digital Health Strategy Execution: The company's future is entirely dependent on its XWELL Digital Health platform. Investors need to assess the viability of its offerings, market adoption rates, and competitive positioning against the 'intense competition' mentioned.
3. Assess Path to Profitability: XWELL targets profitability by late 2027. Investors should scrutinize management's plans for 'stringent cost controls' and revenue growth in the digital health segment to determine if this target is realistic given the current financial performance.
4. Understand Divestiture Impact: The $5.0 million XpresSpa divestiture proceeds are minimal compared to the company's needs. Investors should analyze the long-term financial impact of shedding a revenue-generating segment, even if non-core, and the full transition costs.

Key Dates

• 2025-12-31: Fiscal Year End 2025 Financial Reporting — Release of 10-K detailing a 35% revenue decline to $28.5 million and a 60% wider net loss of $52.3 million, highlighting severe financial challenges and liquidity concerns with cash at $15.2 million.
• 2025-Q4: XpresSpa Segment Divestiture — XWELL divested its non-core XpresSpa airport wellness operations for $5.0 million, marking a complete strategic pivot to its XWELL Digital Health platform and providing a minor cash infusion.
• 2027-Late: Target Profitability Date — The company aims to achieve profitability by late 2027, a critical milestone dependent on aggressive market penetration for digital health offerings and stringent cost controls to reverse significant losses.

Glossary

Impairment Charge

A non-cash expense recognized when the fair value of an asset (or group of assets) is determined to be less than its carrying value on the balance sheet, indicating a permanent reduction in value. (A $15.0 million impairment charge related to the XpresSpa segment significantly contributed to XWELL's $52.3 million net loss, reflecting a write-down of the asset's value prior to its divestiture.)

Digital Health Platform

A technology-driven ecosystem offering health-related services, products, and information, often leveraging mobile applications, artificial intelligence, and data analytics to improve healthcare delivery and outcomes. (XWELL's strategic pivot to its Digital Health platform is a high-stakes move to capture market share in a competitive sector, following the divestiture of its traditional spa business, and is now the company's sole focus.)

Year-Over-Year Comparison

Compared to the prior fiscal year, XWELL's financial performance deteriorated significantly. Total revenue plummeted 35% from $43.8 million to $28.5 million. The net loss widened by 60%, from $32.7 million to $52.3 million. Cash and equivalents saw a drastic reduction from $45.0 million to $15.2 million, indicating severe liquidity challenges. A major strategic shift involved the divestiture of the XpresSpa segment, signaling a complete pivot to digital health, a new core focus not as prominent in previous filings.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share XWEL The Nasdaq Stock Mar
• $0.92 — reference to the closing sale price of $0.92 per share on the Nasdaq Stock Market LL
• $7,044 — ne-year extension totaled approximately $7,044. In January 2024, the program funding a
• $4,000 — pe were expanded, a revenue increase of $4,000, to an estimated $11,044 in revenue for
• $11,044 — nue increase of $4,000, to an estimated $11,044 in revenue for XpresTest with new colle
• $293 — 024 to August 25, 2024). An increase of $293 in revenue for the two week extension b
• $11,337 — week extension brought total revenue to $11,337. The program was again extended in Augu
• $3,763 — was expanded with a revenue increase of $3,763, to an estimated $15,100 in revenue for
• $15,100 — nue increase of $3,763, to an estimated $15,100 in revenue for XpresTest. In February 2
• $22,200 — ear contract with a total base value of $22,200 over three years, and a maximum ceiling
• $24,800 — e years, and a maximum ceiling value of $24,800 within the same timeframe. Naples Wax
• $1,624 — ember 12, 2023, for a purchase price of $1,624, operates a group of upscale hair remov

Filing Documents

• xwel-20251231x10k.htm (10-K) — 3085KB
• xwel-20251231xex23d1.htm (EX-23.1) — 2KB
• xwel-20251231xex23d2.htm (EX-23.2) — 3KB
• xwel-20251231xex31d1.htm (EX-31.1) — 12KB
• xwel-20251231xex31d2.htm (EX-31.2) — 11KB
• xwel-20251231xex32.htm (EX-32) — 7KB
• 0001104659-26-038330.txt ( ) — 14035KB
• xwel-20251231.xsd (EX-101.SCH) — 100KB
• xwel-20251231_cal.xml (EX-101.CAL) — 95KB
• xwel-20251231_def.xml (EX-101.DEF) — 412KB
• xwel-20251231_lab.xml (EX-101.LAB) — 894KB
• xwel-20251231_pre.xml (EX-101.PRE) — 654KB
• xwel-20251231x10k_htm.xml (XML) — 2610KB

BUSINESS

ITEM 1. BUSINESS 4

RISK FACTORS

ITEM 1A. RISK FACTORS 8

UNRESOLVED STAFF COMMENTS

ITEM 1B. UNRESOLVED STAFF COMMENTS 31

CYBERSECU RITY

ITEM 1C. CYBERSECU RITY 31

PROPERTIES

ITEM 2. PROPERTIES 33

LEGAL PROCEEDINGS

ITEM 3. LEGAL PROCEEDINGS 33

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 35 PART II 36

MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 36

[RESERVED]

ITEM 6. [RESERVED] 36

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 37

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 50

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 50

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 50 PART III 51

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 51

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 52

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 52

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 52

PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 52 PART IV 53

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 53

FORM 10-K SUMMARY

ITEM 16. FORM 10-K SUMMARY 58

SIGNATURES

SIGNATURES 59 1 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate, among other matters, to our anticipated financial performance, future revenues or earnings, business prospects, projected ventures, new products and services, anticipated market performance and similar matters. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, the following: our ability to continue as a going concern; the adverse effects of public health epidemics, similar to the coronavirus outbreak, on our business, results of operations and financial condition; our material weaknesses we identified in our internal control over financial reporting, our efforts to remediate such material weaknesses and the timing of remediation; our ability to develop and offer new products and services; our ability to effectively deploy our available cash resources, as well as our ability raise additional capital to fund our operations and business plan, to the extent necessary; general economic conditions and level of consumer and corporate spending on health, wellness and travel; our ability to secure new locations, maintain XpresSpa, Naples Wax and Centers for Disease Control and Prevention ("CDC") bio surveillance testing locations, and ensure continued customer traffic at those locations; our ability to hire a skilled labor force and the costs associated with that labor; our ability to accurately forecast the costs associated with opening new retail locations and maintaining or converting existing ones, and the revenue derived from our retail locations; performance by our Airport Concession Disadvantaged Business Enterprise partners on obligations set forth in our joint venture agreements; our ability to protect our confidential information and custome

BUSINESS

ITEM 1. BUSINESS Overview XWELL is a global wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. As of the date of this Annual Report on Form 10-K, XWELL currently has three reportable operating segments: XpresSpa, XpresTest and Naples Wax Center. On October 25, 2022, the Company changed its name to XWELL, Inc. ("XWELL" or the "Company") from XpresSpa Group, Inc. The Company's common stock, par value $0.01 per share, which had previously been listed under the trading symbol "XSPA" on Nasdaq, now trades under the trading symbol "XWEL". The Company filed an amended and restated certificate of incorporation with the Delaware Secretary of State on October 24, 2022 (as amended, the "Amended and Restated Certificate") reflecting the name change. Rebranding to XWELL aligned the Company's corporate strategy to build a pure-play wellness services company, in both the airport and off-airport marketplaces. All amounts are in thousands, except share, per share, or as otherwise specifically noted. XpresSpa XWELL's subsidiary, XpresSpa Holdings, LLC ("XpresSpa") has been a global airport retailer of spa services through its XpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. As of December 31, 2025, there were 16 domestic XpresSpa locations in total. The Company also had 9 international locations operating as of December 31, 2025, including 2 XpresSpa locations in the Dubai International Airport in the United Arab Emirates, 1 XpresSpa location in the Zayad International Airport in Abu Dhabi, United Arab Emirates, 2 XpresSpa locations in the Schiphol Amsterdam Airport in the Netherlands and 4 XpresSpa locations in the Istanbul Airport in Turkey. Treat, which is operating through XWELL's subsidiary Treat, Inc. ("Treat") is a wellness brand that prov

RISK FACTORS

ITEM 1A. RISK FACTORS We are subject to various risks that may materially harm our business, prospects, financial condition and results of operations. An investment in our common stock is speculative and involves a high degree of risk, and you should carefully consider the risks described below, together with the other information included in this Annual Report on Form 10-K, including the consolidated financial statements and related notes before making an investment decision regarding our common stock. Our business, financial condition, results of operations and the trading price of our common stock could be materially adversely affected by any of the following risks as well as the other risks highlighted elsewhere in this Annual Report on Form 10-K. Although this section discusses all of the material risks currently known to us, additional risks and uncertainties not presently known to us or that we currently deem immaterial also may materially affect our business, financial condition and results of operations. If a